Microbiome’s Moment Approaches: Finch Joins Rival C Diff Companies
Infection Is Common Killer
After a trial failure in 2016, four rival companies could produce pivotal data this year
You may also be interested in...
Tomas de Wouters, one of In Vivo’s 2020 Rising Leaders, has taken on the complex challenge of the microbiome, aiming to design the next generation of microbiome therapeutic candidates targeted at host-microbial interactions.
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
Competing with several other firms to bring the first microbiome-derived therapy to market, Seres says the magnitude of its Phase III efficacy compared to placebo may enough for registrational filing.